Global Risedronate Sodiums Market

Risedronate Sodiums Comprehensive Study by Type (Generic, Branded), Application (Hospital Use, Clinic Use), Risedronate Strength (5 mg, 30 mg, 35 mg), Dosage Form (Capsule, Tablet, Injection) Players and Region - Global Market Outlook to 2026

Risedronate Sodiums Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
The study covers a detailed analysis segmented by key business segments i.e. by type (Generic and Branded) , by application (Hospital Use and Clinic Use) and major geographies.

What is Risedronate Sodiums?
Risedronate sodium is used for the treatment and prevention of osteoporosis in postmenopausal women. It helps to reduce the incidence of vertebral fractures and a composite endpoint of non-vertebral-related fractures. It is indicated for treatment to increase bone mass in man osteoporosis. As per sources, in 2019, Italy recorded an increase in the number of patients with osteoporosis to 4,873 from 4,586 in 2016. It is expected that by 2025, Europe will have a ~33.9 million population (including men & women) with osteoporosis. The rising cases of osteoporosis will increase the growth of the risedronate sodiums market worldwide.

The competition is expected to become even more intense in the years to come due to entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Risedronate Sodiums market analysis report suggests strategies Players can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, including:
  • GlaxoSmithKline (United Kingdom)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Mylan N.V. (United States)
  • Pfizer Inc.(United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Novartis International AG (Switzerland)
  • Mayne Pharma Inc.(United States)
  • Cipla Limited (India)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Sanofi S.A. (France)
  • Sandoz (Germany)
  • Abbott Laboratories (United States)


Companies operating in the global risedronate sodiums market should focus on mergers & acquisitions to improve their market share and overall position. Product launches, research, and expansion of the existing product portfolio are some of the other strategies that should be considered to gain ground in the current risedronate sodiums market during the assessment period.

Market Trend
Demand For Risedronate Sodiums Tablets
Restraints
  • Risk OF Side Effects Such As Indigestion, Diarrhoea, Headache, And Other

Opportunities
Demand For Risedronate Sodiums Tablets and High Growth Opportunities From Emerging Countries

Key highlights of the Global Risedronate Sodiums market Study:
• CAGR of the market during the forecast period 2020-2026
• In-depth information on growth factors that will accelerate the Risedronate Sodiums market in next few years.
• Detailed Insights on futuristic trends and changing consumer behaviour
• Forecast of the Global Risedronate Sodiums market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Risedronate Sodiums Players

Transformation and Important Trigegrs:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Risedronate Sodiums market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Risedronate Sodiums market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Risedronate Sodiums Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Generic
  • Branded
By Application
  • Hospital Use
  • Clinic Use
By Risedronate Strength
  • 5 mg
  • 30 mg
  • 35 mg

By Dosage Form
  • Capsule
  • Tablet
  • Injection

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Cases Of Osteoporosis
      • 3.2.2. Growing Use To Treat Bones Weakening Disease
    • 3.3. Market Challenges
      • 3.3.1. Risedronate Sodium Is Not Recommended For Use In Children Below Age 18
    • 3.4. Market Trends
      • 3.4.1. Demand For Risedronate Sodiums Tablets
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Risedronate Sodiums, by Type, Application, Risedronate Strength , Dosage Form and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Risedronate Sodiums (Value)
      • 5.2.1. Global Risedronate Sodiums by: Type (Value)
        • 5.2.1.1. Generic
        • 5.2.1.2. Branded
      • 5.2.2. Global Risedronate Sodiums by: Application (Value)
        • 5.2.2.1. Hospital Use
        • 5.2.2.2. Clinic Use
      • 5.2.3. Global Risedronate Sodiums by: Dosage Form (Value)
        • 5.2.3.1. Capsule
        • 5.2.3.2. Tablet
        • 5.2.3.3. Injection
      • 5.2.4. Global Risedronate Sodiums Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Risedronate Sodiums: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mylan N.V. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc.(United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis International AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mayne Pharma Inc.(United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cipla Limited (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi S.A. (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Sandoz (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Abbott Laboratories (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Risedronate Sodiums Sale, by Type, Application, Risedronate Strength , Dosage Form and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Risedronate Sodiums (Value)
      • 7.2.1. Global Risedronate Sodiums by: Type (Value)
        • 7.2.1.1. Generic
        • 7.2.1.2. Branded
      • 7.2.2. Global Risedronate Sodiums by: Application (Value)
        • 7.2.2.1. Hospital Use
        • 7.2.2.2. Clinic Use
      • 7.2.3. Global Risedronate Sodiums by: Dosage Form (Value)
        • 7.2.3.1. Capsule
        • 7.2.3.2. Tablet
        • 7.2.3.3. Injection
      • 7.2.4. Global Risedronate Sodiums Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Risedronate Sodiums: by Type(USD Million)
  • Table 2. Risedronate Sodiums Generic , by Region USD Million (2015-2020)
  • Table 3. Risedronate Sodiums Branded , by Region USD Million (2015-2020)
  • Table 4. Risedronate Sodiums: by Application(USD Million)
  • Table 5. Risedronate Sodiums Hospital Use , by Region USD Million (2015-2020)
  • Table 6. Risedronate Sodiums Clinic Use , by Region USD Million (2015-2020)
  • Table 7. Risedronate Sodiums: by Dosage Form(USD Million)
  • Table 8. Risedronate Sodiums Capsule , by Region USD Million (2015-2020)
  • Table 9. Risedronate Sodiums Tablet , by Region USD Million (2015-2020)
  • Table 10. Risedronate Sodiums Injection , by Region USD Million (2015-2020)
  • Table 11. South America Risedronate Sodiums, by Country USD Million (2015-2020)
  • Table 12. South America Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 13. South America Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 14. South America Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 15. South America Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 16. Brazil Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 17. Brazil Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 18. Brazil Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 19. Brazil Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 20. Argentina Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 21. Argentina Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 22. Argentina Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 23. Argentina Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 24. Rest of South America Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 25. Rest of South America Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 26. Rest of South America Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 27. Rest of South America Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 28. Asia Pacific Risedronate Sodiums, by Country USD Million (2015-2020)
  • Table 29. Asia Pacific Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 30. Asia Pacific Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 31. Asia Pacific Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 32. Asia Pacific Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 33. China Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 34. China Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 35. China Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 36. China Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 37. Japan Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 38. Japan Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 39. Japan Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 40. Japan Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 41. India Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 42. India Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 43. India Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 44. India Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 45. South Korea Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 46. South Korea Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 47. South Korea Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 48. South Korea Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 49. Taiwan Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 50. Taiwan Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 51. Taiwan Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 52. Taiwan Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 53. Australia Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 54. Australia Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 55. Australia Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 56. Australia Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 57. Rest of Asia-Pacific Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 58. Rest of Asia-Pacific Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 59. Rest of Asia-Pacific Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 60. Rest of Asia-Pacific Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 61. Europe Risedronate Sodiums, by Country USD Million (2015-2020)
  • Table 62. Europe Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 63. Europe Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 64. Europe Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 65. Europe Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 66. Germany Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 67. Germany Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 68. Germany Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 69. Germany Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 70. France Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 71. France Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 72. France Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 73. France Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 74. Italy Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 75. Italy Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 76. Italy Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 77. Italy Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 78. United Kingdom Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 79. United Kingdom Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 80. United Kingdom Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 81. United Kingdom Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 82. Netherlands Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 83. Netherlands Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 84. Netherlands Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 85. Netherlands Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 86. Rest of Europe Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 87. Rest of Europe Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 88. Rest of Europe Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 89. Rest of Europe Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 90. MEA Risedronate Sodiums, by Country USD Million (2015-2020)
  • Table 91. MEA Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 92. MEA Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 93. MEA Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 94. MEA Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 95. Middle East Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 96. Middle East Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 97. Middle East Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 98. Middle East Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 99. Africa Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 100. Africa Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 101. Africa Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 102. Africa Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 103. North America Risedronate Sodiums, by Country USD Million (2015-2020)
  • Table 104. North America Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 105. North America Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 106. North America Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 107. North America Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 108. United States Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 109. United States Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 110. United States Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 111. United States Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 112. Canada Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 113. Canada Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 114. Canada Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 115. Canada Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 116. Mexico Risedronate Sodiums, by Type USD Million (2015-2020)
  • Table 117. Mexico Risedronate Sodiums, by Application USD Million (2015-2020)
  • Table 118. Mexico Risedronate Sodiums, by Risedronate Strength USD Million (2015-2020)
  • Table 119. Mexico Risedronate Sodiums, by Dosage Form USD Million (2015-2020)
  • Table 120. Company Basic Information, Sales Area and Its Competitors
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Risedronate Sodiums: by Type(USD Million)
  • Table 133. Risedronate Sodiums Generic , by Region USD Million (2021-2026)
  • Table 134. Risedronate Sodiums Branded , by Region USD Million (2021-2026)
  • Table 135. Risedronate Sodiums: by Application(USD Million)
  • Table 136. Risedronate Sodiums Hospital Use , by Region USD Million (2021-2026)
  • Table 137. Risedronate Sodiums Clinic Use , by Region USD Million (2021-2026)
  • Table 138. Risedronate Sodiums: by Dosage Form(USD Million)
  • Table 139. Risedronate Sodiums Capsule , by Region USD Million (2021-2026)
  • Table 140. Risedronate Sodiums Tablet , by Region USD Million (2021-2026)
  • Table 141. Risedronate Sodiums Injection , by Region USD Million (2021-2026)
  • Table 142. South America Risedronate Sodiums, by Country USD Million (2021-2026)
  • Table 143. South America Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 144. South America Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 145. South America Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 146. South America Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 147. Brazil Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 148. Brazil Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 149. Brazil Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 150. Brazil Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 151. Argentina Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 152. Argentina Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 153. Argentina Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 154. Argentina Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 155. Rest of South America Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 156. Rest of South America Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 157. Rest of South America Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 158. Rest of South America Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 159. Asia Pacific Risedronate Sodiums, by Country USD Million (2021-2026)
  • Table 160. Asia Pacific Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 161. Asia Pacific Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 162. Asia Pacific Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 163. Asia Pacific Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 164. China Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 165. China Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 166. China Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 167. China Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 168. Japan Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 169. Japan Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 170. Japan Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 171. Japan Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 172. India Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 173. India Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 174. India Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 175. India Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 176. South Korea Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 177. South Korea Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 178. South Korea Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 179. South Korea Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 180. Taiwan Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 181. Taiwan Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 182. Taiwan Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 183. Taiwan Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 184. Australia Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 185. Australia Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 186. Australia Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 187. Australia Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 188. Rest of Asia-Pacific Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 189. Rest of Asia-Pacific Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 190. Rest of Asia-Pacific Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 191. Rest of Asia-Pacific Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 192. Europe Risedronate Sodiums, by Country USD Million (2021-2026)
  • Table 193. Europe Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 194. Europe Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 195. Europe Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 196. Europe Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 197. Germany Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 198. Germany Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 199. Germany Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 200. Germany Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 201. France Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 202. France Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 203. France Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 204. France Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 205. Italy Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 206. Italy Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 207. Italy Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 208. Italy Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 209. United Kingdom Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 210. United Kingdom Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 211. United Kingdom Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 212. United Kingdom Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 213. Netherlands Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 214. Netherlands Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 215. Netherlands Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 216. Netherlands Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 217. Rest of Europe Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 218. Rest of Europe Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 219. Rest of Europe Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 220. Rest of Europe Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 221. MEA Risedronate Sodiums, by Country USD Million (2021-2026)
  • Table 222. MEA Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 223. MEA Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 224. MEA Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 225. MEA Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 226. Middle East Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 227. Middle East Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 228. Middle East Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 229. Middle East Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 230. Africa Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 231. Africa Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 232. Africa Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 233. Africa Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 234. North America Risedronate Sodiums, by Country USD Million (2021-2026)
  • Table 235. North America Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 236. North America Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 237. North America Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 238. North America Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 239. United States Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 240. United States Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 241. United States Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 242. United States Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 243. Canada Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 244. Canada Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 245. Canada Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 246. Canada Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 247. Mexico Risedronate Sodiums, by Type USD Million (2021-2026)
  • Table 248. Mexico Risedronate Sodiums, by Application USD Million (2021-2026)
  • Table 249. Mexico Risedronate Sodiums, by Risedronate Strength USD Million (2021-2026)
  • Table 250. Mexico Risedronate Sodiums, by Dosage Form USD Million (2021-2026)
  • Table 251. Research Programs/Design for This Report
  • Table 252. Key Data Information from Secondary Sources
  • Table 253. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Risedronate Sodiums: by Type USD Million (2015-2020)
  • Figure 5. Global Risedronate Sodiums: by Application USD Million (2015-2020)
  • Figure 6. Global Risedronate Sodiums: by Dosage Form USD Million (2015-2020)
  • Figure 7. South America Risedronate Sodiums Share (%), by Country
  • Figure 8. Asia Pacific Risedronate Sodiums Share (%), by Country
  • Figure 9. Europe Risedronate Sodiums Share (%), by Country
  • Figure 10. MEA Risedronate Sodiums Share (%), by Country
  • Figure 11. North America Risedronate Sodiums Share (%), by Country
  • Figure 12. Global Risedronate Sodiums share by Players 2020 (%)
  • Figure 13. Global Risedronate Sodiums share by Players (Top 3) 2020(%)
  • Figure 14. Global Risedronate Sodiums share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 18. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 20. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 22. Pfizer Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 23. Pfizer Inc.(United States) Revenue: by Geography 2020
  • Figure 24. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 25. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 26. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 28. Mayne Pharma Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 29. Mayne Pharma Inc.(United States) Revenue: by Geography 2020
  • Figure 30. Cipla Limited (India) Revenue, Net Income and Gross profit
  • Figure 31. Cipla Limited (India) Revenue: by Geography 2020
  • Figure 32. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2020
  • Figure 34. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 35. Sanofi S.A. (France) Revenue: by Geography 2020
  • Figure 36. Sandoz (Germany) Revenue, Net Income and Gross profit
  • Figure 37. Sandoz (Germany) Revenue: by Geography 2020
  • Figure 38. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 39. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 40. Global Risedronate Sodiums: by Type USD Million (2021-2026)
  • Figure 41. Global Risedronate Sodiums: by Application USD Million (2021-2026)
  • Figure 42. Global Risedronate Sodiums: by Dosage Form USD Million (2021-2026)
  • Figure 43. South America Risedronate Sodiums Share (%), by Country
  • Figure 44. Asia Pacific Risedronate Sodiums Share (%), by Country
  • Figure 45. Europe Risedronate Sodiums Share (%), by Country
  • Figure 46. MEA Risedronate Sodiums Share (%), by Country
  • Figure 47. North America Risedronate Sodiums Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline (United Kingdom)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Mylan N.V. (United States)
  • Pfizer Inc.(United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Novartis International AG (Switzerland)
  • Mayne Pharma Inc.(United States)
  • Cipla Limited (India)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Sanofi S.A. (France)
  • Sandoz (Germany)
  • Abbott Laboratories (United States)
Additional players considered in the study are as follows:
Yangtze River Pharmaceutical Group (China) , Henan Topfond Pharmaceutical Co., Ltd (China) , Beijing SL Pharmaceutical Co., Ltd. (China) , Kunming Jida Pharmaceutical Co., Ltd (China) , Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd (China)
Select User Access Type

Key Highlights of Report


Apr 2021 237 Pages 70 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Risedronate Sodiums Market Quantitative research analysis
Global Risedronate Sodiums Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Risedronate Sodiums Market is heading robustly to achieve new growth cycle.
The Concentration Rate of Global Risedronate Sodiums market is dominated by Players to generate healthy valuation by 2026.
Companies that are profiled in Global Risedronate Sodiums Market are GlaxoSmithKline (United Kingdom), F. Hoffmann-La Roche AG (Switzerland), Mylan N.V. (United States), Pfizer Inc.(United States), Teva Pharmaceutical Industries Ltd. (Israel), Novartis International AG (Switzerland), Mayne Pharma Inc.(United States), Cipla Limited (India), Takeda Pharmaceutical Company Limited (Japan), Sanofi S.A. (France), Sandoz (Germany) and Abbott Laboratories (United States) etc.

Know More About Global Risedronate Sodiums Market Report?

Have a Query? Click Here

Other Related Reports

Palbociclib Comprehensive Study by Type (Tablets, Capsules), Distribution Channel (Online Pharmacies, Retail Pharmacies), End-Users (Hospitals, Diagnostic Centres, Research Institutes), Strength (5mg...
$ 3500
Antibiotics Active Pharmaceutical Ingredient Comprehensive Study by Type (Penicillin Antibiotics, Cephalosporins, Carbapenem Antibiotics), Application (Pharmaceutical Companies, Contract Manufacturin...
$ 3450
Levothyroxine Sodium Tablet Comprehensive Study by Application (Hospital, Specialty Clinic), Treatment (Goiters, Thyroid cancer), Packaging (Bottle, Blister), Dosage (25mcg – 50mcg, 50mcg – 75mcg, 75...
$ 3350
Trulicity Comprehensive Study by Distribution Channel (Specialty Pharma Retail Stores, Hospitals Pharma), Dosage (Less than 1mg, 1mg - 2mg, 2mg - 3mg, 3mg - 4mg, More than 4mg) Players and Region - G...
$ 3500
Rilonacept Drugs Comprehensive Study by Application (Pediatric, Adult, Geriatric), Treatment (Familial Cold Urticaria Syndrome (FCUS), Muckle-Wells Syndrome (MWS), Neonatal Onset Multisystem Inflamma...
$ 3450
Cannabis Indica Oil Comprehensive Study by Type (Organic Cannabis Oil, Non-Organic Cannabis Oil), Application (Recreational, Medical) Players and Region - Global Market Outlook to 2026
$ 3500